Vitro Biopharma (VTRO) Form 3 Vitro Biopharma / Nathan Haas ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Haas Nathan

(Last) (First) (Middle)

3200 CHERRY CREEK DRIVE SOUTH, SUITE 720

(Street)

DENVER, CO 80209

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/11/2022

3. Issuer Name and Ticker or Trading Symbol
Vitro Biopharma, Inc. [ NONE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,881,299	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	08/01/2031	Common Stock	1,000,000	0.5	D
Employee Stock Option (Right to Buy)	(2)	10/01/2031	Common Stock	500,000	0.5	D
Warrant (Right to Buy)	08/01/2021	07/31/2024	Common Stock	120,000	0.5	D
Warrant (Right to Buy)	08/01/2021	07/31/2026	Common Stock	120,000	1	D
Warrant (Right to Buy)	10/22/2021	10/21/2024	Common Stock	400,000	0.5	D
Warrant (Right to Buy)	10/22/2021	10/21/2026	Common Stock	400,000	1	D

Explanation of Responses:

1. The option became exercisable as to 200,000 shares on August 1, 2022, and will become exercisable as to (i) 200,000 shares on August 1, 2023, (ii) 200,000 shares on August 1, 2024, (iii) 200,000 shares on August 1, 2025, and (iv) 200,000 shares on August 1, 2026.

2. The option became exercisable as to 100,000 shares on October 1, 2022, and will become exercisable as to (i) 100,000 shares on October 1, 2023, (ii) 100,000 shares on October 1, 2024, (iii) 100,000 shares on October 1, 2025, and (iv) 100,000 shares on October 1, 2026.

	/s/ Nathan Haas	11/14/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.